Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Myovant Licenses European Rights for Relugolix Combo to Gedeon Richter
Myovant Sciences, now a subsidiary of Sumitomo Dainippon Pharma, said on March 31 that it will grant Hungary’s Gedeon Richter exclusive rights to develop and commercialize its relugolix combination tablet (relugolix + estradiol + norethindrone) for uterine fibroids and endometriosis…
To read the full story
Related Article
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Relugolix Combo Tablet Filed in EU for Uterine Fibroids
March 11, 2020
BUSINESS
- Keytruda Keeps Grip on Top Spot in July Drug Sales: Encise
August 17, 2026
- Japan Ethical Drug Sales Jump 9% in June: Crecon
August 17, 2026
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…